Recently, a new study defining specific expression profiles in LSCs CD34+/CD38+ and CD34+/CD38− on AML and CML BM samples with the intent to identify novel targets has been performed [50]. Here, CD38 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.